The Pro115Gln polymorphism within the PPAR γ2 gene has no epidemiological impact on morbid obesity

被引:17
作者
Hamer, OW
Forstner, D
Ottinger, I
Ristow, M
Bollheimer, LC
Schölmerich, J
Palitzsch, KD
机构
[1] Univ Regensburg, Dept Internal Med 1, D-8400 Regensburg, Germany
[2] German Inst Nutr, DIFE, KLE, Bergholz Potsdam, Germany
关键词
peroxisome-proliferator-activated receptor gamma 2 Pro115Gln; obesity; polymorphism; epidemiology;
D O I
10.1055/s-2002-33072
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The peroxisome-proliferator-activated receptor gamma2 (PPAR gamma2) is a transcriptional key regulator of adipocyte differentiation. PPARgamma2 can be inactivated by phosphorylation of a serine residue at position 114. A point mutation leading to an amino acid exchange at position 115 (Pro115Gln) was shown to preclude serine phosphorylation and to consecutively accelerate adipocyte differentiation emphasizing the pathophysiological relevance of this mutation. So far, four markedly obese heterozygote carriers of the Pro-115Gln mutation (body mass index 37.9-47.3 kgxm(-2)) have been identified in a circumscribed study population. In order to evaluate the epidemiological relevance of the Pro115Gln mutation in morbid obesity we screened the DNA of all subjects with a body mass index greater than 35 kgxm-2 who had participated in a nationwide German epidemiological field survey. There was no homozygote or heterozygote carrier of the Pro115Gln polymorphism among them. We conclude that the Pro115Gln polymorphism within the PPAR gamma2 gene has no relevant epidemiological impact on morbid obesity in Germany. It needs further investigation whether this polymorphism might play a role in related metabolic disorders.
引用
收藏
页码:230 / 234
页数:5
相关论文
共 32 条
[1]  
ADAMS M, 1997, J BIOL CHEM, V272, P5125
[2]   Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - No alteration in adipose tissue of obese and NIDDM patients [J].
Auboeuf, D ;
Rieusset, J ;
Fajas, L ;
Vallier, P ;
Frering, V ;
Riou, JP ;
Staels, P ;
Auwerx, J ;
Laville, M ;
Vidal, H .
DIABETES, 1997, 46 (08) :1319-1327
[3]   PPARγ, the ultimate thrifty gene [J].
Auwerx, J .
DIABETOLOGIA, 1999, 42 (09) :1033-1049
[4]  
Bouchard C, 1996, CIBA F SYMP, V201, P108
[5]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366
[6]   The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes [J].
Clement, K ;
Hereberg, S ;
Passinge, B ;
Galan, P ;
Varroud-Vial, M ;
Shuldiner, AR ;
Beamer, BA ;
Charpentier, G ;
Guy-Grand, B ;
Froguel, P ;
Vaisse, C .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (03) :391-393
[7]   Thiazolidinediones: a new class of antidiabetic drugs [J].
Day, C .
DIABETIC MEDICINE, 1999, 16 (03) :179-192
[8]   Peroxisome proliferator-activated receptors: Nuclear control of metabolism [J].
Desvergne, B ;
Wahli, W .
ENDOCRINE REVIEWS, 1999, 20 (05) :649-688
[9]   Variation in the gene for human peroxisome proliferator activated receptor γ (PPARγ) does not play a major role in the development of morbid obesity [J].
Evans, D ;
Mann, WA ;
de Heer, J ;
Michel, U ;
Wendt, D ;
Kortner, B ;
Wolf, A ;
Beisiegel, U .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (05) :647-651
[10]   PPARγ3 mRNA:: a distinct PPARγ mRNA subtype transcribed from an independent promoter [J].
Fajas, L ;
Fruchart, JC ;
Auwerx, J .
FEBS LETTERS, 1998, 438 (1-2) :55-60